HUNTINGTON’S DISEASE: CURRENT ADVANCES AND FUTURE PROSPECTS
DOI:
https://doi.org/10.22159/ijpps.2021v13i12.42979Keywords:
Huntington’s disease, Symptom, Gene, TreatmentAbstract
Huntington’s disease is a neurodegenerative disease which is caused by dominantly inherited cytosine-adenine-guanine trinucleotide repeat expansion in the huntingtin gene of chromosome 4. Present survey reveals 2.7 per 100000 people are affected by huntington’s disease worldwide. The symptoms present with these patients are progressive motor, cognitive and psychiatric disorders. The early symptoms are chorea and loss of balance. This review aims to observe the present data available concerning huntington’s disease, symptoms, age of onset, risk factors, benefits of early diagnosis and genetic attribution. There is no cure for the disease. The article searched, selected and reviewed were from google scholar, medscape, NIH MedlinePlus, PubMed database using MeSH terms huntington’s disease, recent therapeutic advancement from 2003 to July 2021 with no language restriction and additional studies were included from the reference lists of relevant articles. The present review provides clinical features, diagnosis, symptomatic management and ongoing research. Hence this review will have an impact to create awareness for the society and researchers to find future treatment for Huntington’s disease.
Downloads
References
Novak MJU, Tabrizi SJ. Huntington’s disease. BMJ. 2010;340(jun30 4):c3109. doi: 10.1136/bmj.c3109.
Machiela E, Southwell AL. Biological aging and the cellular pathogenesis of Huntington’s disease. J Huntingtons Dis. 2020;9(2):115-28. doi: 10.3233/JHD-200395, PMID 32417788.
Charles J, Lessey L, Rooney J, Prokop I, Yearwood K, Da Breo H, Rooney P, Walker RH, Sobering AK. Presentation and care of a family with Huntington disease in a resource-limited community. J Clin Mov Disord. 2017;4:4. doi: 10.1186/s40734-017-0050-6. PMID 28413688.
Myers RH. Huntington’s disease genetics. Neurotherapeutics. 2004;1(2):255-62. doi: 10.1602/neurorx.1.2.255.
Caron NS, Wright GEB, Hayden MR, Adam MP, Ardinger HH, Pagon RA. Huntington disease. In: Seattle: University of Washington. Seattle; 2020. p. 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1305/. [Last accessed on 20 Jul 2021]
Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18(1):91-8. doi: 10.31887/DCNS.2016.18.1/pnopoulos, PMID 27069383.
Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40. doi: 10.1186/1750-1172-5-40, PMID 21171977.
Saranya S, Sharon KJ, Arya MA, Sachin T, Amrutha VU, Arya GK. An updated review on the application of dendrimers as successful nanocarriers for brain delivery of therapeutic moieties. Int J Appl Pharm. 2021;13:1-9.
Ajitkumar A, De Jesus O. Huntington disease. StatPearls: 2021. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK559166. [Last accessed on 20 Jul 2021]
Huntington disease: MedlinePlus Genetics. Available from: https://medlineplus/.gov/genetics/condition/Huntington-disease. [Last accessed on 30 Jul 2021]
Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16(10):837-47. doi: 10.1016/S1474-4422(17)30280-6, PMID 28920889.
Huntington G. On chorea george Huntington. J Neuropsychiatry Clin Neurosci. 2003;15(1):109-12. doi: 10.1176/jnp.15.1.109, PMID 12556582.
Raymond LA, Andre VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252-73. doi: 10.1016/ j.neuroscience.2011.08.052, PMID 21907762.
Krishnendu PR, Arjun B, Vibina K, Nivea CTS, Drisya NK, Radhika M. Review on evaluating the role of NSAIDs for the treatment of Alzheimer’s disease. Int J Appl Pharm. 2021;13(1):91-4.
Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474-83. doi: 10.1007/s11910-011-0215-x, PMID 21861097.
Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, Zugno E, Caletti E. Neuropsychiatric burden in Huntington’s disease. Brain Sci. 2017;7(6):67. doi: 10.3390/ brainsci7060067, PMID 28621715.
Nambron R, Silajdzic E, Kalliolia E, Ottolenghi C, Hindmarsh P, Hill NR, Costelloe SJ, Martin NG, Positano V, Watt HC, Frost C, Bjorkqvist M, Warner TT. A metabolic study of Huntington’s disease. PLOS One. 2016;11(1):e0146480. doi: 10.1371/journal.pone.0146480, PMID 26744893.
Schiefer J, Werner CJ, Reetz K. Clinical diagnosis and management in early Huntington’s disease: a review. Degener Neurol Neuromuscul Dis. 2015;5:37-50. doi: 10.2147/DNND.S49135, PMID 32669911.
Mestre TA, Forjaz MJ, Mahlknecht P, Cardoso F, Ferreira JJ, Reilmann R, Sampaio C, Goetz CG, Cubo E, Martinez Martin P, Stebbins GT. Members of the movement disorder society committee on rating scales development. Rating scales for motor symptoms and signs in Huntington’s disease: critique and recommendations. Mov Disord Clin Pract. 2018;5(2):111-7. doi: 10.1002/mdc3.12571, PMID 30363393.
Chokhawala K, Stevens L. Antipsychotic medications in StatPearls. Treasure Island, (FL): StatPearls Publishing; 2021. Available from: http://www.ncbi.nlm.nih.gov/ books/NBK519503. [Last accessed on 27 Jul 2021].
Voysey ZJ, Barker RA, Lazar AS. The treatment of sleep dysfunction in neurodegenerative disorders. Neurotherapeutics. 2021;18(1):202-16. doi: 10.1007/s13311-020-00959-7, PMID 33179197.
Shih HI, Lin CC, Tu YF, Chang CM, Hsu HC, Chi CH, Kao CH. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. Med (Baltim). 2015;94(17):e809. doi: 10.1097/MD.0000000000000809, PMID 25929937.
Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013;65(1):105-42. doi: 10.1124/pr.111.005512, PMID 23300133.
Song H, Li H, Guo S, Pan Y, Fu Y, Zhou Z, Li Z, Wen X, Sun X, He B, Gu H, Zhao Q, Wang C, An P, Luo S, Hu Y, Xie X, Lu B. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington’s disease-associated phenotypes. Brain. 2018;141(6):1782-98. doi: 10.1093/brain/awy081, PMID 29608652.
Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153-60. doi: 10.1007/s13311-013-0244-z, PMID 24366610.
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25(1):24-34. doi: 10.1111/ene.13413, PMID 28817209.
Christodoulou CC, Demetriou CA, Zamba-Papanicolaou E. Dietary intake, Mediterranean diet adherence and caloric intake in Huntington’s disease: a review. Nutrients. 2020;12(10):e2946. doi: 10.3390/nu12102946, PMID 32992896.
Rodrigues FB, Wild EJ. Huntington’s disease clinical trials corner: April 2020. J Huntingtons Dis. 2020;9(2):185-97. doi: 10.3233/JHD-200002, PMID 32250312.
Leavitt BR, Kordasiewicz HB, Schobel SA. Huntingtin-lowering therapies for Huntington disease: a review of the evidence of potential benefits and risks. JAMA Neurol. 2020;77(6):764-72. doi: 10.1001/jamaneurol.2020.0299, PMID 32202594.
McKenzie H. Novartis sees glimmer of hope for Branaplam in Huntington’s disease. Available from: https://www.biospace.com/article/novartis-sees-glimmer-of-hope-for-branaplam-in-huntington-s-disease. [Last accessed on 20 Oct 2020]
Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci. 2020;21(6):2146. doi: 10.3390/ijms21062146, PMID 32245050.
Harding R. Huntington’s disease clinical trial round up. In: Dr Fox L, editor. Available from: https://en.hdbuzz.net/303. [Last accessed on 15 Jun 2021]
La Spada AR. A novel therapy for huntington’s disease. Cerebrum. 2018;2018:11-8. PMID 30746028.
Carpanini SM, Torvell M, Morgan BP. Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol. 2019;10:362. doi: 10.3389/fimmu.2019.00362, PMID 30886620.
Sanjay CK. Phase 2a study of ANX005, a humanized anti-C1q mAb, in patients with huntington disease, Huntington study group annual conference. Clinical Trial Round-up Session; 2020. Availablefrom: https://annexonbio.com/documents/HSG-ANX005-Clinical-Trial-Round-up-2020_10_08.pdf.
Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek F, Rullmann M, Sattler B, Patt M, Gerhards T, Strauss M, Kluge A, Brust P, Savola JM, Gordon MF, Geva M, Hesse S, Barthel H, Hayden MR, Sabri O. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. Eur J Nucl Med Mol Imaging. 2021;48(4):1103-15. doi: 10.1007/s00259-020-05030-3, PMID 32995944.
Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97(A):46-59. doi: 10.1016/j.nbd. 2016.10.006, PMID 27818324.
Robert S, Lahue RS. New developments in Huntington’s disease and other triplet repeat diseases: DNA repair turns to the dark side. Neuronal Signal. 2020;4(4):NS20200010:NS20200010. doi: 10.1042/NS20200010, PMID 33224521.
Rodrigues FB, Ferreira JJ, Wild EJ. Huntington’s disease clinical trials corner: June 2019. J Huntingtons Dis. 2019;8(3):363-71. doi: 10.3233/JHD-199003, PMID 31381524.
Uhlyar S, Rey JA. Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia. P T. 2018;43(6):328-31. PMID 29896031.
Efficacy, safety, and tolerability of valbenazine for the treatment of chorea associated with Huntington disease (KINECT-HD). Available from: https://clinicaltrials.gov/ct2/show/NCT04102579. [Last accessed on 17 Jul 2021].
Landwehrmeyer GB, Fitzer Attas CJ, Giuliano JD, Gonçalves N, Anderson KE, Cardoso F, Ferreira JJ, Mestre TA, Stout JC, Sampaio C. Data analytics from enroll-HD, a global clinical research platform for Huntington'’s disease. Mov Disord Clin Pract. 20162017;4(2):212-24. doi: 10.1002/mdc3.12388, PMID 30363395.
Wild EJ. Huntington'’s disease: the most curable incurable brain disorder? Biomedicine. 2016;8:3-4. doi: 10.1016/ j.ebiom. 2016.05.023, PMID 27428401.
Wild E. HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington’s disease (HDClarity). Available from: https://clinicaltrials.gov/ ct2/show/NCT02855476. [Last accessed on 02 Jul 2021]
Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington'’s disease: Iinterventions in early clinical development and newer methodological approaches. Mov Disord. 2014;29(11):1419-28. doi: 10.1002/mds.26021, PMID 25216371.
Paulsen JS. Neurobiological predictors of Huntington’s disease (PREDICT-HD) (PREDICT-HD). Available from: https://clinicaltrials.gov/ct2/show/NCT00051324. [Last accessed on 16 Jun 2021].
Published
How to Cite
Issue
Section
Copyright (c) 2021 BRIGHT LEMUEL JOHN N., AKILA RAMANATHAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
